iSTEP - an mHealth Physical Activity and Diet Intervention for Persons With HIV

September 25, 2023 updated by: Brook Henry, University of California, San Diego
HIV is associated with a pattern of neurocognitive deficits, metabolic dysfunction, and an elevated risk for cardiovascular disease (CVD), phenomena that remain untreated despite the use of medications to control the disease. This proposal will examine the effect of a personalized, automated, interactive mobile phone text message intervention (iSTEP) designed to increase moderate physical activity (PA), decrease sedentary behavior (SB), and promote a healthy Mediterranean-style diet (MedDiet) in persons living with HIV (PLWH). The investigators propose that participants who receive the iSTEP intervention will increase the amount of physical activity, improve their diet, show a reduction in risk factors for CVD, and exhibit improved neurocognitive performance.

Study Overview

Status

Completed

Conditions

Study Type

Interventional

Enrollment (Actual)

100

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Contact Backup

Study Locations

    • California
      • San Diego, California, United States, 92103
        • HIV Neurobehavioral Research Program

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Description

Inclusion Criteria:

  • ability to provide informed consent
  • HIV infection documented at the University of California, San Diego (UCSD) HIV Neurobehavioral Research Program (HNRP) or assessed by an HIV test at screening
  • proficient in English
  • physically capable of participating in moderate PA as screened by the Physical Activity Readiness Questionnaire
  • consent from primary care physician to participate in the study
  • able to consume walnuts - no nut allergies

Exclusion Criteria:

  • any physical conditions that would prevent moderate physical activity or where moderate physical activity would represent a health risk for the individual, including a history of myocardial infarction or stroke
  • unwillingness or inability to participate in daily text messaging
  • tree nut allergy that would prevent walnut consumption or other food restrictions that would prevent participation in the Mediterranean-style diet intervention (e.g., unable to eat fish or use olive oil for cooking).

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Prevention
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Active Comparator: Control Arm
Participants will wear a Fitbit but will not receive any additional elements of the iSTEP intervention.
Wearing Physical Activity Monitor
Experimental: iSTEP PA intervention
Participants will wear a Fitbit and receive interactive daily text messages that are designed to motivate moderate physical activity (PA) and reduce sedentary behavior, including setting weekly goals to increase average daily step counts.
Physical Activity Intervention
Physical Activity and Diet Intervention
Experimental: iSTEP PA and diet intervention
Participants will wear a Fitbit and receive interactive daily text messages that are designed to motivate moderate physical activity (PA), reduce sedentary behavior, and promote adherence to a Mediterranean-style diet. Participants will also be administered diet counseling from a registered dietitian and receive weekly feedback on both physical activity and diet behaviors.
Physical Activity Intervention
Physical Activity and Diet Intervention

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Physical activity - steps per day
Time Frame: 6 months
Average number of daily steps recorded by the Fitbit
6 months
Diet History Questionnaire (DHQ)
Time Frame: Change from baseline to the 6-month visit after intervention
DHQ assessment of the percent of fat, carbohydrate, and protein intake in participant diet over the past month
Change from baseline to the 6-month visit after intervention

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Sedentary behavior - minutes per day
Time Frame: Change from first week (Week 1) to last week (Week 24) of the intervention
Average daily minutes of sedentary behavior (counts < 100/minute) quantified by GT3X Actigraph
Change from first week (Week 1) to last week (Week 24) of the intervention
Fitness - 6-minute walk test (6MWT)
Time Frame: Change from baseline to the 6-month visit after intervention
Time to complete 6-minute walk test around a 30 yard course; the score is the total yard distance completed.
Change from baseline to the 6-month visit after intervention
Physical activity - moderate physical activity measured by actigraph
Time Frame: Change from first week (Week 1) to last week (Week 24) of the intervention
Average daily minutes of moderate physical activity quantified by GT3X Actigraph
Change from first week (Week 1) to last week (Week 24) of the intervention
Physical activity - daily energy expenditure
Time Frame: Change from first week (Week 1) to last week (Week 24) of the intervention
Seven-day Physical Activity Recall - kilocalories per day
Change from first week (Week 1) to last week (Week 24) of the intervention
Polyunsaturated fatty acids (PUFA) in plasma
Time Frame: Change from baseline to the 6-month visit after intervention
One reported value of the total PUFA amount, consisting of the sum of α-linoleic acid (ALA), eicosapentaenoic acid (EPA), docosahexaenoic acid (DHA), and docosapentaenoic acid (DPA) levels in plasma.
Change from baseline to the 6-month visit after intervention
Carotenoids in plasma
Time Frame: Change from baseline to the 6-month visit after intervention
One reported value of the total carotenoid amount, consisting of the sum of alpha-carotene, beta-carotene, lutein, lycopene and betacryptoxanthin levels in plasma.
Change from baseline to the 6-month visit after intervention
Interleukin-6 (IL6)
Time Frame: Change from baseline to the 6-month visit after intervention
Levels of IL6 in plasma
Change from baseline to the 6-month visit after intervention
C-reactive protein (CRP)
Time Frame: Change from baseline to the 6-month visit after intervention
Levels of CRP in plasma
Change from baseline to the 6-month visit after intervention
D-dimer
Time Frame: Change from baseline to the 6-month visit after intervention
Levels of D-dimer in plasma
Change from baseline to the 6-month visit after intervention
Tumor necrosis factor alpha (TNFa)
Time Frame: Change from baseline to the 6-month visit after intervention
Levels of TNFa in plasma
Change from baseline to the 6-month visit after intervention
Total cholesterol (TC)
Time Frame: Change from baseline to the 6-month visit after intervention
Levels of TC in plasma
Change from baseline to the 6-month visit after intervention
Low density lipoprotein cholesterol (LDL-C)
Time Frame: Change from baseline to the 6-month visit after intervention
Levels of LDL-C in plasma
Change from baseline to the 6-month visit after intervention
High density lipoprotein cholesterol (HDL-C)
Time Frame: Change from baseline to the 6-month visit after intervention
Levels of HDL-C in plasma
Change from baseline to the 6-month visit after intervention
Triglycerides
Time Frame: Change from baseline to the 6-month visit after intervention
Levels of triglycerides in plasma
Change from baseline to the 6-month visit after intervention
Wechsler Adult Intelligence Scale (WAIS) Digit Symbol
Time Frame: Change from baseline to the 6-month visit after intervention
Neurocognitive assessment
Change from baseline to the 6-month visit after intervention
WAIS Symbol Search
Time Frame: Change from baseline to the 6-month visit after intervention
Neurocognitive assessment
Change from baseline to the 6-month visit after intervention
Trail Making Test Part A
Time Frame: Change from baseline to the 6-month visit after intervention
Neurocognitive assessment
Change from baseline to the 6-month visit after intervention
Trail Making Test Part B
Time Frame: Change from baseline to the 6-month visit after intervention
Neurocognitive assessment
Change from baseline to the 6-month visit after intervention
Hopkins Verbal Learning Test - Revised
Time Frame: Change from baseline to the 6-month visit after intervention
Neurocognitive assessment
Change from baseline to the 6-month visit after intervention
Brief Visuospatial Memory Test - Revised
Time Frame: Change from baseline to the 6-month visit after intervention
Neurocognitive assessment
Change from baseline to the 6-month visit after intervention
Wisconsin Card Sorting Test
Time Frame: Change from baseline to the 6-month visit after intervention
Neurocognitive assessment
Change from baseline to the 6-month visit after intervention
Controlled Oral Word Association Test
Time Frame: Change from baseline to the 6-month visit after intervention
Neurocognitive assessment
Change from baseline to the 6-month visit after intervention
Category Fluency
Time Frame: Change from baseline to the 6-month visit after intervention
Neurocognitive assessment
Change from baseline to the 6-month visit after intervention
WAIS Letter-Number Sequencing
Time Frame: Change from baseline to the 6-month visit after intervention
Neurocognitive assessment
Change from baseline to the 6-month visit after intervention
Paced Auditory Serial Addition Task
Time Frame: Change from baseline to the 6-month visit after intervention
Neurocognitive assessment
Change from baseline to the 6-month visit after intervention
Grooved Pegboard Test.
Time Frame: Change from baseline to the 6-month visit after intervention
Neurocognitive assessment
Change from baseline to the 6-month visit after intervention

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Brook L Henry, Ph.D., University of California, San Diego

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

March 1, 2018

Primary Completion (Actual)

May 31, 2023

Study Completion (Actual)

May 31, 2023

Study Registration Dates

First Submitted

April 11, 2017

First Submitted That Met QC Criteria

April 18, 2017

First Posted (Actual)

April 21, 2017

Study Record Updates

Last Update Posted (Actual)

September 28, 2023

Last Update Submitted That Met QC Criteria

September 25, 2023

Last Verified

September 1, 2023

More Information

Terms related to this study

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on HIV/AIDS

Clinical Trials on Control Arm

3
Subscribe